{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:37:38Z","timestamp":1761824258551,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10637-020-00988-1","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T08:03:57Z","timestamp":1597651437000},"page":"210-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Erlotinib and bevacizumab in elderly patients \u226575\u00a0years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations"],"prefix":"10.1007","volume":"39","author":[{"given":"Yoichiro","family":"Aoshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-7119","authenticated-orcid":false,"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kusagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Uto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"issue":"21","key":"988_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"issue":"2","key":"988_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"issue":"8","key":"988_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735\u2013742. https:\/\/doi.org\/10.1016\/S1470-2045(11)70184-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"988_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, de Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Mu\u00f1oz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239\u2013246. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X","journal-title":"Lancet Oncol"},{"key":"988_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Non-small cell lung cancer. version 3. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf (Accessed May 7 2020)"},{"issue":"20","key":"988_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/jnci\/89.20.1489","volume":"89","author":"WB Ershler","year":"1997","unstructured":"Ershler WB, Longo DL (1997) Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89(20):1489\u20131497. https:\/\/doi.org\/10.1093\/jnci\/89.20.1489","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"988_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1378\/CHEST.128.2.947","volume":"128","author":"C Gridelli","year":"2005","unstructured":"Gridelli C, Shepherd FA (2005) Chemotherapy for elderly patients with non-small cell lung Cancer: a review of the evidence. Chest. 128(2):947\u2013957. https:\/\/doi.org\/10.1378\/CHEST.128.2.947","journal-title":"Chest."},{"issue":"1","key":"988_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-015-2784-x","volume":"76","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Inui N, Asada K, Karayama M, Matsuda H, Yokomura K, Koshimizu N, Imokawa S, Yamada T, Shirai T, Kasamatsu N, Suda T (2015) Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Cancer Chemother Pharmacol 76(1):155\u2013161. https:\/\/doi.org\/10.1007\/s00280-015-2784-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"988_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, Di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145\u2013147. https:\/\/doi.org\/10.1038\/nm988","journal-title":"Nat Med"},{"issue":"5","key":"988_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391\u2013400. https:\/\/doi.org\/10.1038\/nrd1381","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"988_CR11","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","volume":"7","author":"J Ma","year":"2008","unstructured":"Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7(12):3670\u20133684. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0715","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"988_CR12","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"issue":"8","key":"988_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, Von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27(8):1227\u20131234. https:\/\/doi.org\/10.1200\/JCO.2007.14.5466","journal-title":"J Clin Oncol"},{"key":"988_CR14","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","volume":"377","author":"RS Herbst","year":"2011","unstructured":"Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 377:1846\u20131854. https:\/\/doi.org\/10.1016\/S0140-6736(11)60545-X","journal-title":"Lancet."},{"key":"988_CR15","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15:1236\u20131244. https:\/\/doi.org\/10.1016\/S1470-2045(14)70381-X","journal-title":"Lancet Oncol"},{"issue":"2","key":"988_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"3","key":"988_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"988_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M (2019) Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20(5):625\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(19)30035-X","journal-title":"Lancet Oncol"},{"issue":"12","key":"988_CR19","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","volume":"88","author":"H Wildiers","year":"2003","unstructured":"Wildiers H, Guetens G, De Boeck G et al (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88(12):1979\u20131986. https:\/\/doi.org\/10.1038\/sj.bjc.6601005","journal-title":"Br J Cancer"},{"issue":"13","key":"988_CR20","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","volume":"13","author":"PV Dickson","year":"2007","unstructured":"Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CYC, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13(13):3942\u20133950. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0278","journal-title":"Clin Cancer Res"},{"issue":"3","key":"988_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajpath.2012.05.023","volume":"181","author":"S Takeuchi","year":"2012","unstructured":"Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S (2012) Dual inhibition of met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol 181(3):1034\u20131043. https:\/\/doi.org\/10.1016\/j.ajpath.2012.05.023","journal-title":"Am J Pathol"},{"issue":"1","key":"988_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JTO.0b013e3182370e02","volume":"7","author":"J Laskin","year":"2012","unstructured":"Laskin J, Crin\u00f2 L, Felip E, Franke F, Gorbunova V, Groen H, Jiang GL, Reck M, Schneider CP (2012) Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 7(1):203\u2013211. https:\/\/doi.org\/10.1097\/JTO.0b013e3182370e02","journal-title":"J Thorac Oncol"},{"issue":"1","key":"988_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2007.13.1144","volume":"26","author":"SS Ramalingam","year":"2008","unstructured":"Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH, Eastern Cooperative Oncology Group (2008) Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. J Clin Oncol 26(1):60\u201364. https:\/\/doi.org\/10.1200\/JCO.2007.13.1144","journal-title":"J Clin Oncol"},{"issue":"4","key":"988_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clon.2014.12.002","volume":"27","author":"AJ Wozniak","year":"2015","unstructured":"Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel DR, Leon L, Fish S, Flick ED, Hazard SJ, Lynch TJ Jr (2015) Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. J Clin Oncol 27(4):187\u2013196. https:\/\/doi.org\/10.1016\/j.clon.2014.12.002","journal-title":"J Clin Oncol"},{"issue":"7","key":"988_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"issue":"2","key":"988_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"issue":"2","key":"988_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A, for the North-East Japan Study Group (2020) Gefitinib alone versus gefitinib plus chemotherapy for non\u2013small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38(2):115\u2013123. https:\/\/doi.org\/10.1200\/JCO.19.01488","journal-title":"J Clin Oncol"},{"issue":"2","key":"988_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","volume":"38","author":"V Noronha","year":"2020","unstructured":"Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K (2020) Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol 38(2):124\u2013136. https:\/\/doi.org\/10.1200\/JCO.19.01154","journal-title":"J Clin Oncol"},{"issue":"12","key":"988_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M, Chu Q, Cortot A, Pujol JL, Moro-Sibilot D, Fabre E, Lamour C, Bischoff H, Kollmeier J, Reck M, Kimmich M, Engel-Riedel W, Hammerschmidt S, Sch\u00fctte W, Syrigos K, Ho JCM, Au KH, Novello S, Ardizzoni A, Pasello G, Gregorc V, del Conte A, Galetta D, Takahashi T, Nakagawa K, Nishio M, Yoh K, Seto T, Imamura F, Kumagai T, Hotta K, Goto Y, Hosomi Y, Sakai H, Takiguchi Y, Kim YH, Kurata T, Yamaguchi H, Daga H, Okamoto I, Satouchi M, Ikeda S, Kasahara K, Atagi S, Azuma K, Kumagai T, Aoe K, Kumagai T, Aoe K, Horio Y, Yamamoto N, Tanaka H, Watanabe S, Nogami N, Ozaki T, Koyama R, Hirashima T, Kaneda H, Tomii K, Fujita Y, Seike M, Nishimura N, Kato T, Ichiki M, Saka H, Hirano K, Nakahara Y, Sugawara S, Park K, Kim SW, Min YJ, Lee HW, Kang JH, An HJ, Lee KH, Kim JS, Lee GW, Lee SY, Alexandru A, Udrea AA, Juan-Vidal \u00d3, Nadal-Alforja E, Gil-Bazo I, Ponce-Aix S, Paz-Ares L, Rubio-Viqueira B, Alonso Garcia M, Felip Font E, Fuentes Pradera J, Coves Sarto J, Lin MC, Su WC, Hsia TC, Chang GC, Wei YF, Chiu CH, Shih JY, Su J, Cicin I, Goksel T, Harputluoglu H, Ozyilkan O, Henning I, Popat S, Hatcher O, Mileham K, Acoba J, Garon E, Jung G, Raj M, Martin W, Dakhil S (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(12):1655\u20131669. https:\/\/doi.org\/10.1016\/S1470-2045(19)30634-5","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00988-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:54:18Z","timestamp":1678510458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00988-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00988-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no actual or potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}